Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Cash Flow (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Net Cash Flow data on record, last reported at $33.6 million in Q4 2023.

  • For Q4 2023, Net Cash Flow rose 138.83% year-over-year to $33.6 million; the TTM value through Dec 2023 reached -$57.7 million, down 159.89%, while the annual FY2025 figure was $5.3 million, 134.53% up from the prior year.
  • Net Cash Flow reached $33.6 million in Q4 2023 per CGEM's latest filing, up from -$77.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $277.4 million in Q2 2022 and bottomed at -$169.9 million in Q2 2021.
  • Average Net Cash Flow over 4 years is $2.2 million, with a median of -$13.8 million recorded in 2020.
  • The widest YoY moves for Net Cash Flow: up 801.47% in 2021, down 3069.18% in 2021.
  • A 4-year view of Net Cash Flow shows it stood at $126.9 million in 2020, then plummeted by 122.33% to -$28.3 million in 2021, then crashed by 205.34% to -$86.5 million in 2022, then soared by 138.83% to $33.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $33.6 million in Q4 2023, -$77.0 million in Q3 2023, and $19.7 million in Q2 2023.